Literature DB >> 22641663

Expression of dihydropyrimidine dehydrogenase, orotate phosphoribosyl transferase and thymidylate synthase in patients with primary colorectal cancer, and associations with site of first metastasis.

Yoshito Akagi1, Tetsushi Kinugasa, Tomoaki Mizobe, Akihiko Kawahara, Masayoshi Kage, Kazuo Shirouzu.   

Abstract

AIM: The activity of the widely used anticancer drug 5-fluorouracil (5-FU) is determined by the presence of several enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), and thymidylate synthase (TS). This study compared the expression levels of these enzymes between primary colorectal cancer with and without distant metastases, and examined whether these expression patterns are associated with hematogenous metastasis.
MATERIALS AND METHODS: Among 40 patients with colorectal cancer, 20 had no metastasis and 20 had distant metastasis. Strong expression on immunohistochemistry was classified as positive, while weak, moderate or no expression was classified as negative.
RESULTS: Positive expressions of DPD, OPRT and TS in primary colorectal cancer tissue were seen in 47.5%, 75% and 20%, respectively. However, no relationships were observed among the expressions of DPD, OPRT and TS. Expressions of OPRT (p=0.029) and TS (p=0.017) in primary tissues were significantly associated with hematogenous metastasis. Patterns of the expression of the three enzymes varied, and were classified in six ways. A tendency was seen for primary colorectal cancer with DPD-high expression to have liver metastasis and for that with DPD-low expression, to have lung metastasis.
CONCLUSION: High expression levels of OPRT and TS in colorectal cancer appear to be significantly involved in metastasis after curative surgery. The organs in which metastases arise may be controlled by the expression of DPD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22641663

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.

Authors:  Nancy E Kemeny; Joanne F Chou; Marinela Capanu; Alexandra N Gewirtz; Andrea Cercek; T Peter Kingham; William R Jarnagin; Yuman C Fong; Ronald P DeMatteo; Peter J Allen; Jinru Shia; Celina Ang; Efsevia Vakiani; Michael I D'Angelica
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

Review 2.  Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.

Authors:  Pan Xie; Jun-Luan Mo; Jin-Hong Liu; Xi Li; Li-Ming Tan; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Cell Oncol (Dordr)       Date:  2020-05-30       Impact factor: 6.730

3.  Differences in chemosensitivity between primary and metastatic tumors in colorectal cancer.

Authors:  Katsushi Takebayashi; Eiji Mekata; Hiromichi Sonoda; Tomoharu Shimizu; Hisanori Shiomi; Shigeyuki Naka; Yoshihiro Endo; Tohru Tani
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

4.  Comment on "influence of orotate phosphoribosyl transferase levels on tumor prognosis and response to chemotherapy".

Authors:  Shailendra Kapoor
Journal:  J Oncol       Date:  2012-10-03       Impact factor: 4.375

Review 5.  Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer.

Authors:  Stephan Paschke; Sakhavat Jafarov; Ludger Staib; Ernst-Dietrich Kreuser; Catharina Maulbecker-Armstrong; Marc Roitman; Torbjörn Holm; Curtis C Harris; Karl-Heinrich Link; Marko Kornmann
Journal:  Int J Mol Sci       Date:  2018-08-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.